Regeneron stock just slipped on a banana peel, hitting a 52-week low at $493.15 before closing at $496.06. Despite this dip, ...

Regeneron Pharmaceuticals saw a downgrade from Wells Fargo, slicing its stock rating from "overweight" to "equal weight" and ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

SINGAPORE] Amid a flurry of delistings from the Singapore Exchange (SGX), one more privatisation offer – especially that for ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Guggenheim maintains a “Buy” rating for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) despite challenges, including the delayed regulatory submissions of Itepekimab. The delay in Itepekimab’s approval ...

The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Ulta Beauty ( ULTA) was the best-performing stock in the S&P 500 after the beauty products retailer beat profit and sales ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

Regeneron's performance in the first quarter was dismal ... NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer ...

Following the announcement, Regeneron’s stock price fell by 8.19% in pre-market trading, reflecting investor disappointment. This performance aligns with recent analyst sentiment, as ...